Carboplatin Enhances the Activity of Human Transient Receptor Potential Ankyrin 1 through the Cyclic AMP-Protein Kinase A-A-Kinase Anchoring Protein (AKAP) Pathways.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
03 Jul 2019
Historique:
received: 14 06 2019
revised: 01 07 2019
accepted: 02 07 2019
entrez: 7 7 2019
pubmed: 7 7 2019
medline: 21 12 2019
Statut: epublish

Résumé

Carboplatin, an anticancer drug, often causes chemotherapy-induced peripheral neuropathy (PN). Transient receptor potential ankyrin 1 (TRPA1), a non-selective cation channel, is a polymodal nociceptor expressed in sensory neurons. TRPA1 is not only involved in pain transmission, but also in allodynia or hyperalgesia development. However, the effects of TRPA1 on carboplatin-induced PN is unclear. We revealed that carboplatin induced mechanical allodynia and cold hyperalgesia, and the pains observed in carboplatin-induced PN models were significantly suppressed by the TRPA1 antagonist HC-030031 without a change in the level of TRPA1 protein. In cells expressing human TRPA, carboplatin had no effects on changes in intracellular Ca

Identifiants

pubmed: 31277262
pii: ijms20133271
doi: 10.3390/ijms20133271
pmc: PMC6651390
pii:
doi:

Substances chimiques

A Kinase Anchor Proteins 0
TRPA1 Cation Channel 0
Carboplatin BG3F62OND5
Cyclic AMP E0399OZS9N
Cyclic AMP-Dependent Protein Kinases EC 2.7.11.11

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 23790315
Organisme : Japan Society for the Promotion of Science
ID : 25860199
Organisme : Japan Society for the Promotion of Science
ID : 16K08568
Organisme : Japan Society for the Promotion of Science
ID : 15K10522
Organisme : Japan Society for the Promotion of Science
ID : 15K08215
Organisme : Japan Society for the Promotion of Science
ID : 18K08858
Organisme : The Nakatomi Foundation
ID : none

Références

J Clin Oncol. 1999 Jan;17(1):409-22
pubmed: 10458260
Br J Cancer. 2000 Feb;82(4):966-72
pubmed: 10732773
Pain. 2005 Oct;117(3):368-76
pubmed: 16150543
Nat Cell Biol. 2005 Nov;7(11):1066-73
pubmed: 16228013
Handb Exp Pharmacol. 2007;(179):347-62
pubmed: 17217068
Mol Pain. 2007 Dec 17;3:40
pubmed: 18086313
J Peripher Nerv Syst. 2008 Mar;13(1):27-46
pubmed: 18346229
Brain. 2008 May;131(Pt 5):1241-51
pubmed: 18356188
Eur J Neurosci. 2008 Mar;27(5):1131-42
pubmed: 18364033
Pain. 2008 Sep 15;138(3):604-16
pubmed: 18381233
J Clin Invest. 2008 May;118(5):1899-910
pubmed: 18398506
Neuron. 2008 Aug 14;59(3):450-61
pubmed: 18701070
Pain. 2010 Mar;148(3):431-7
pubmed: 20056530
Mol Pain. 2010 Mar 05;6:15
pubmed: 20205720
Pain. 2010 May;149(2):393-405
pubmed: 20378247
Mol Pain. 2010 Nov 24;6:82
pubmed: 21106058
Pain. 2011 Jul;152(7):1621-31
pubmed: 21481532
Neuroscience. 2011 Oct 13;193:440-51
pubmed: 21763756
J Neurochem. 2012 Mar;120(6):1036-47
pubmed: 22182301
J Neurosci. 2012 May 16;32(20):7091-101
pubmed: 22593077
Mol Pain. 2012 Jul 28;8:55
pubmed: 22839205
Cancer Res. 2013 May 15;73(10):3120-31
pubmed: 23477783
Sci Rep. 2013;3:2005
pubmed: 23774285
PLoS One. 2014 Mar 17;9(3):e91746
pubmed: 24637403
J Pharmacol Sci. 2014;125(1):91-8
pubmed: 24784702
PLoS One. 2014 Sep 04;9(9):e106485
pubmed: 25188410
Anesth Analg. 2015 Apr;120(4):790-8
pubmed: 25642661
PLoS One. 2015 Apr 30;10(4):e0124875
pubmed: 25928068
Sci Rep. 2015 Nov 06;5:16078
pubmed: 26542342
Mol Pain. 2015 Nov 13;11:69
pubmed: 26567040
Transl Neurosci. 2015 Mar 18;6(1):111-116
pubmed: 28123794
Sci Rep. 2017 May 12;7(1):1842
pubmed: 28500286
Biol Pharm Bull. 2017;40(7):947-953
pubmed: 28674258
Front Physiol. 2017 Nov 01;8:878
pubmed: 29163216
Neuropeptides. 2018 Feb;67:95-101
pubmed: 29274843
Front Physiol. 2017 Dec 13;8:1040
pubmed: 29326595
Gene. 2019 Jan 5;680:43-50
pubmed: 30244138
Mol Pain. 2019 Jan-Dec;15:1744806919840098
pubmed: 30857460
Semin Oncol. 1995 Oct;22(5 Suppl 12):80-5
pubmed: 7481867
Science. 1995 Jan 6;267(5194):108-11
pubmed: 7528941
Semin Oncol. 1994 Oct;21(5 Suppl 12):114-8
pubmed: 7992063
Bone Marrow Transplant. 1995 Sep;16(3):353-8
pubmed: 8535306
Semin Oncol. 1995 Dec;22(6 Suppl 14):32-4
pubmed: 8553081
Science. 1996 Mar 15;271(5255):1589-92
pubmed: 8599116
J Neurol Neurosurg Psychiatry. 1998 May;64(5):667-9
pubmed: 9598687
Ann Oncol. 1998 Apr;9(4):443-7
pubmed: 9636837

Auteurs

Kanako Miyano (K)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.

Seiji Shiraishi (S)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.

Koichiro Minami (K)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.
Emergency Life-Saving Technique Academy of Tokyo (ELSTA TOKYO), Hachioji-shi, Tokyo 192-0364, Japan.
Department of Anesthesiology and Critical Care Medicine, Jichi Medical University, Tochigi 329-0498, Japan.

Yuka Sudo (Y)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.
Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.

Masami Suzuki (M)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.

Toru Yokoyama (T)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.
Emergency Life-Saving Technique Academy of Tokyo (ELSTA TOKYO), Hachioji-shi, Tokyo 192-0364, Japan.
Department of Anesthesiology and Critical Care Medicine, Jichi Medical University, Tochigi 329-0498, Japan.

Kiyoshi Terawaki (K)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.

Miki Nonaka (M)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan.

Hiroaki Murata (H)

Department of Anesthesiology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.

Yoshikazu Higami (Y)

Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.
Translational Research Center, Research Institute of Science and Technology, Tokyo University of Science, Chiba 278-8510, Japan.

Yasuhito Uezono (Y)

Division of Cancer Pathophysiology, National Cancer Research Institute, Tokyo 104-0045, Japan. yuezono@ncc.go.jp.
Division of Supportive Care Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo 104-0045, Japan. yuezono@ncc.go.jp.
Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center, Tokyo 104-0045, Japan. yuezono@ncc.go.jp.
Department of Comprehensive Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan. yuezono@ncc.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH